Latest Content

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

USP's Annual Drug Shortages Report reveals a sharp rise in product discontinuations, driven by unsustainable generic pricing, upstream geographic concentration, and manufacturing complexity.

Danny Williams breaks down direct-to-patient distribution and his outlook on where pharma 3PLs are headed over the next five years.

After adding 160 more drugs, TrumpRx tops 800 prescription offerings. Here's what the latest MFN-driven expansion means for pricing and access.

Danny Williams discusses how AI has moved from experimental pilots to full operational deployment across supply chain functions, and how cell and gene therapies are reshaping the logistics industry.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

A new CMS demonstration launching July 1 will offer eligible Part D beneficiaries access to branded obesity drugs at a $50 copay. Here's what manufacturers, payers, and pharmacies need to know.

EVERSANA's Danny Williams breaks down the most consequential operational shifts in pharma 3PL over the past five years, from full-pallet distribution to integrated commercialization support for complex, targeted therapies.

In this week's Pharma Pulse, a Bluesight survey flags hospital pharmacy's top concerns, the Wegovy pill is introduced to the UAE, and more.

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

Cencora will support US distribution of Kite's Yescarta and Tecartus, reducing administrative burdens and expanding CAR T-cell therapy access at authorized treatment centers.

Cameron Olig explains how transparency and direct access models can help pharma close the gap between drug pricing, distribution and the patient.

ThermoSafe expands US VIP manufacturing amid surging biologics demand and growing pressure to reduce overseas cold chain packaging risk.